Q Bio Raises $40M For Preventative Health Platform In a16z-Led Series B

, a digital health platform, has emerged from stealth with a $40 million round of funding led by (a16z).

The Series B financing brings the company鈥檚 total funding since its inception in late 2015 to $58 million. Other backers include , , , Thirty5 Venturers, and .

Because digital health platform is such a broad term, let鈥檚 break down what it means in this case. The Redwood City California-based startup claims it can give 鈥渕embers鈥� a web-based in 鈥�75 minutes or less.鈥�

The premise behind the company is to help identify health issues before they become worse, or as it claims: 鈥淭o give individuals a deeper understanding of their own body and how it鈥檚 changing over time so they have more control over their own health.鈥�

Indeed, most of us don鈥檛 even know we鈥檙e sick until symptoms start popping up to alert us. In some cases such as certain forms of cancer–it can already be too late. Q Bio says its platform can actually identify signs of disease at the earliest stages, before symptoms arise. If this is true, I鈥檇 say it鈥檚 revolutionary.

The way it works seems straightforward. Members register online and the company begins aggregating and digitizing their medical history. On exam day, members anonymously check in for a 75- to 90-minute exam. Two weeks later, a Q 鈥渆xpert鈥� will review the results over a 鈥渟ecure鈥� video chat in which members鈥� physicians are welcome to join.

With each additional visit, Q claims, its HIPAA-compliant platform gets more sensitive to surfacing anomalous changes in your body, then tailors the set of measurements gathered based on these anomalies and changing risk factors.

In summary, membership includes a fully comprehensive exam including a full body MRI, saliva, blood and urine analysis, a summary and a 30-minute telemedicine review of the health of each of your body鈥檚 systems. Health data is continuously updated for one year and stored in the company’s BioVault with lifetime access to review and share.

co-founder serves as Q Bio鈥檚 CEO. As part of this new round of funding, Andreessen Horowitz General Partner joins Q Bio鈥檚 board, along with from Khosla Ventures.

Background

Kaditz co-founded the company with his own misdiagnoses from over a decade ago in mind.

Since then, he said, he鈥檚鈥渋magined a day when everything about a person鈥檚 body could be quickly measured, shared and analyzed.鈥�

“It聽took some time to figure out some of the scaling issues and to wait for certain technologies to be cheap enough and mature enough,” Kaditz told 萝莉视频 News.聽“Our technology allows us to gather more clinical information, more quantitatively, faster and cheaper than anything else and it will only get faster and less expensive over time. We allow for a separation of where you go to get your body measured and where your doctor actually is.”

Over the past few years, the company has stealthily worked on fine-tuning its imaging protocols to determine the 鈥渕ost clinically relevant set of biomarkers鈥� to include in its platform. It has 25 employees, up from 17 a year ago.

Currently Q Bio has a location in its home base of Redwood City but is looking several locations in major metro areas outside of that location.

Indeed, initial demand was “overwhelming,” Kaditz said, so the company has created a waitlist.

“Some members have chosen to fly to our Redwood City location rather than wait for a new location to open,” he added. At the end of the day, Q Bio believes “executive physicals should not be just for executives.”

a16z’s Pande in a written statement said that鈥淨 Bio makes true preventive medicine possible today.鈥�

鈥淏y measuring everything from blood to imaging and more in a longitudinal way, patients can have personalized baselines and physicians the data and power to understand, interpret and utilize this data to personalize care,” he added.

Illustration:

Stay up to date with recent funding rounds, acquisitions, and more with the 萝莉视频 Daily.

萝莉视频